Could a once-every-few-weeks IV infusion tame rheumatoid arthritis?

NCT ID NCT07704580

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether giving sarilumab (Kevzara) through an IV with longer intervals between doses is safe and works well for adults with moderate-to-severe rheumatoid arthritis. Participants receive the drug intravenously, with or without other standard arthritis medications. Researchers measure drug levels in the blood and monitor for side effects over about six months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental intravenous form of the drug sarilumab (also known as Kevzara)
What this could lead to
If successful, this could offer people with rheumatoid arthritis a more convenient dosing option with fewer injections.
What could go wrong
This is an early-phase study with a small number of participants, so results may not apply broadly. The longer dosing intervals might not control symptoms as effectively as the standard regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ClinRx Research - Plano- Site Number : 8400015

    RECRUITING

    Plano, Texas, 75023, United States

  • Encore Medical Research - Hollywood- Site Number : 8400010

    RECRUITING

    Hollywood, Florida, 33024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.